Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT01582672
Title Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)
Acronym ADAPT
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors Argos Therapeutics
Age Groups: adult
Covered Countries USA | ITA | GBR | ESP | CAN

No variant requirements are available.